Biotechnology stock indexes slipped on Tuesday, led bySynergen Inc.'s stock (NASDAQ:SYGN), which fell $4.25 a share,closing at $56.75. Company spokesman Paul Laland said he wasunaware of any news that would have affected the company'sstock. Clinical trial results of Synergen's highly touted sepsisdrug, Antril, are due to be analyzed this quarter, but the trialshave not yet been unblinded, Laland said.

The biotechnology stock indexes reflected the drop in high-profile biotech stocks. The AMEX Biotechnology Stock Index fell5.25 points to 149.55, while the Chicago Board Option ExchangeBiotech Stock Index dropped 5.53 to 142.42.

Individual stocks that lost more than $2 a share for the dayincluded Amgen Inc. (AMGN), off $2.25 a share to $63.75;Biogen Inc. (BGEN), down $2.25 a share to $38.50; Chiron Corp.(CHIR), slipping $2.25 a share to $50.50; GensiaPharmaceuticals Inc. (GNSA), down $2.50 a share to $23.50;Genzyme Corp. (GENZ), off $2.25 a share to $38.25; and ImCloneSystems Inc. (IMCL), down $2 a share to $12.

(c) 1997 American Health Consultants. All rights reserved.